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Abstract 
Objective: Kraepelin considered downward course a hallmark of schizophrenia, but others 
suggested that outcomes usually stabilize or improve after treatment initiation. We investigated 
this question in the first U.S. study to follow an epidemiologically-defined cohort with psychotic 
disorders for 20 years after first hospitalization. 
Method: The Suffolk County Mental Health Project recruited first-admission patients with 
psychosis from all inpatient units of Suffolk County, New York (72% response rate). Participants 
were assessed in person six times over two decades; 373 completed 20-year follow-up (68% of 
survivors); 175 had schizophrenia/schizoaffective disorder. Global Assessment of Functioning 
(GAF), psychotic symptoms, and mood symptoms were rated at each assessment. We used 
month 6 as a reference, when nearly all participants were discharged from the index 
hospitalization. 
Results: In schizophrenia, mean GAF scores declined from 49 (month 6) to 36 (year 20). 
Negative and positive symptoms also worsened (Cohen’s ds = .45 - .73). Other psychoses had 
higher GAF initially (mean ~64), but it declined by 9 points. Worsening began between years 5 
and 8. Neither aging nor changes in antipsychotic treatment accounted for the declines. In all 
disorders, depression improved and manic symptoms remained low across the 20 years. 
Conclusions: We found substantial symptom burden across disorders that increased with time 
and ultimately may undo initial treatment gains. Previous studies suggested that better health 
care delivery models may preempt this decline. In the U.S., these care needs are often not met, 
and addressing them is an urgent priority.  
[243 words]  
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Emil Kraepelin1 considered declining course a distinguishing feature of schizophrenia 
(dementia praecox) in contrast to the non-declining, episodic course of mood disorders with 
psychosis (MoDWP). Others challenged this view, suggesting that a downward trajectory is not 
typical of schizophrenia and outcomes tend to improve over time2,3. Prospective investigations of 
clinical course—evolution of symptom burden over time—in first episode/admission psychosis 
(FEP) can provide key evidence for answering this question, as they employ a well-defined early 
starting point. 
 Numerous studies followed FEP cohorts in the short- and mid-term. A systematic review 
found global outcome to be fairly stable across the first decade of illness4. Recent 10-year 
follow-ups of two seminal FEP cohorts observed that positive symptoms initially improve and 
then stabilize, while negative symptoms remain largely unchanged5 and only a minority of 
participants is continuously ill6. Overall, this research did not suggest a decline in the first decade 
of illness, but the second decade may be different. 
 The international Determinants of Outcome of Severe Mental Disorders (DOSMeD) 
project is the only prospective study to follow FEP patients for two decades7,8. More than half of 
participants with schizophrenia had good outcome (Global Assessment of Functioning [GAF] 
score >60), and 50% improved over the interval whereas only 23% declined8. However, limited 
interim information precluded charting of illness trajectories. Also, these analyses included only 
one small sample (N = 56) from the U.S., and large cross-national differences in outcomes were 
observed8. The most similar U.S. project, the Chicago Follow-up Study assessed an early course 
sample six times over two decades after admission with psychosis. In schizophrenia, global 
outcome improved through year 7.5 and then stabilized with about 20% having good outcome 9 . 
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Repeated assessment provided a detailed picture of illness course, but conclusions are limited by 
a sample drawn primarily from a private hospital.    
    Less is known about long-term course of MoDWP. The DOSMeD study did not analyze 
this group separately, but presented all non-schizophrenia psychoses together, finding better 
outcomes (two-thirds had GAF >60) and course (69% improving and only 12% declining) than 
in schizophrenia8. In the Chicago Follow-up Study, non-schizophrenia psychoses also had better 
course, with global outcome improving through year 4.5 and then stabilizing with about 40% 
having good outcome9. Another investigation found that only 8% of MoDWP were continuously 
ill during the decade after first admission6. No studies have charted illness trajectories of this 
group over 20 years. 
 Furthermore, previous long-term studies largely focused on global outcome and overall 
pattern of course. Consequently, trajectories of specific symptoms are less understood. At least 
four clearly distinct dimensions of psychotic symptoms have been identified: reality distortion 
(i.e., hallucinations, delusions), disorganization, inexpressivity, and apathy-asociality10,11. This 
scheme is an elaboration of the classic 3-dimensional model12 through division of negative 
symptoms into apathy-asociality and inexpressivity. Mood symptoms—depression and mania—
also play a prominent role in psychotic disorders13,14. These six dimensions follow distinct 
trajectories15 yet long-term data on changes in many of these symptoms are lacking. 
 The present study sought to address the aforementioned limitations of long-term follow-
up studies of clinical course by: (1) examining an epidemiologically-defined FEP cohort, (2) 
tracing trajectories of the six symptom dimensions as well as global outcome (GAF) across two 
decades, (3) following a sufficiently large MoDWP group to precisely chart its course and 
compare to course of schizophrenia, and (4) using longitudinal consensus diagnoses to define 
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study groups with high accuracy. The present study is the first to put the four techniques 
together, offering an unprecedented opportunity to clarify the disagreement between modern 
views of illness course and Kraepelin’s descriptions. Moreover, this also is the first study to 
attempt direct replication of DOSMeD’s long-term findings in the U.S.  
Methods 
Participants 
The cohort was assembled by the Suffolk County Mental Health Project, an 
epidemiologic study of first-admission psychosis11,16,17. Participants were recruited from the 12 
psychiatric inpatient units of Suffolk County, NY, 1990-1995. Inclusion criteria were first 
admission either current or within six months, clinical evidence of psychosis, ages 15-60, IQ 
>70, proficiency with English, resident of Suffolk County, and no apparent medical etiology. 
The study was approved annually by the institutional review boards of Stony Brook University 
and the participating hospitals. 
We initially interviewed 675 participants (72% of referrals); 628 of them met the 
eligibility criteria. Follow-ups were conducted at 6-month, 24-month, 48-month, 10-year, and 
20-year points. Seventy nine participants died during the 20 years. Of the 549 survivors, 373 
were successfully contacted at year 20 and constitute the analysis sample. Of them, 68.9% lived 
in Suffolk County, 6.4% moved to another county in NY, and 24.7% moved to another state. 
Non-participants were similar to the analysis sample on study variables at baseline 
(demographics, diagnosis, and symptoms; Table 1), but they were less likely to be Caucasian 
(67.4% vs. 77.7%) and had more severe reality distortion symptoms (Cohen’s d = .23). For the 
analysis sample (N=373), we had 2,046 observations across six waves (i.e., data were 91.4% 
complete). Follow-ups that were done over the phone (277 across waves) did not allow 
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behavioral ratings necessary for scoring inexpressivity, resulting in 1,769 observations available 
for inexpressivity. Primary analyses employed maximum likelihood estimation and thus used all 
available data.    
 
Measures 
Interviews were conducted by master’s level mental health professionals. Medical 
records and interviews with significant others were solicited at every assessment. This multi-
source information was used to complete the following rating scales about past-month 
symptoms: the Scale for the Assessment of Negative Symptoms (SANS 18 the Scale for the 
Assessment of Positive Symptoms (SAPS19) the Brief Psychiatric Rating Scale (BPRS 20 and the 
Structured Clinical Interview for DSM (SCID 21) In the present cohort, we scored four reliable 
factor-analytically derived subscales from the SANS and SAPS: Inexpressivity (α ≥ .88, 9 
items), Apathy-Asociality (α ≥ .81, 6 items), Reality Distortion (α ≥ .80, 14 items), and 
Disorganization (α ≥ .72, 11 items)11. Mania was operationalized with the excitement rating of 
the BPRS. Depression symptoms were assessed with the current depression module of the SCID 
administered without skip-outs. We constructed a nine-symptom depression composite (range: 9 
– 27) with excellent reliability (α ≥ .81) and validity11,17. All ratings were highly reliable 
(eMethods). 
Primary DSM-IV diagnosis was formulated at the 10-year point by consensus of study 
psychiatrists using all available information17. The same process was performed in previous 
waves, including 6-month assessment. Diagnoses were grouped into five categories: 
schizophrenia/schizophreniform/schizoaffective disorder, bipolar disorder with psychosis, 
depression with psychosis, substance-induced psychosis, and other/undetermined psychosis (e.g., 
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psychotic disorder not otherwise specified). Psychiatrists made consensus ratings of the Global 
Assessment of Functioning (GAF) for the best month of the year before interview, an index that 
captures both symptoms burden and functional impairment. At year 20, psychiatrists also rated 
the overall pattern of clinical course following the DOSMeD criteria (see eMethods)22. For 
interpretability, we grouped eight course categories into three: single episode (i.e., baseline 
episode resolved, no recurrence), multiple episodes, and continuous illness (i.e., no remission). 
Data Analysis 
We investigated trajectories of each disorder on seven outcome measures: GAF (primary 
measure) and the six symptom dimensions. All participants were highly symptomatic and 
hospitalized at baseline; therefore, baseline could not be included in the model and we started 
charting trajectories from month 6. We focus on mean disorder trajectories here. Within-group 
heterogeneity was reported previously11.  
First, we examined clinical course in bivariate analyses, comparing outcomes at 
subsequent follow-ups to month 6 using paired t-tests. We compared outcomes between 
disorders using independent samples t-tests. Next, we charted trajectories of disorders across all 
waves by fitting multi-level spline regression models with random intercept (see eMethods)23-25. 
Models were fit for each disorder separately; they estimated trajectories of individual participants 
and then calculated the mean trajectory for the group. These analyses took advantage of variation 
in follow-ups around target dates (i.e., some were done late and others early), which allowed us 
to chart trajectories through year 23. However, data were limited for years 5 – 8 and 13 – 16 (< 
20 observations/year) and these portions of trajectories were estimated less precisely. Spline 
regression is a piecewise regression that allows different slopes in different segments of the 
predictor variable. We considered up to 3 segments (the largest number suggested by descriptive 
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analyses). Transition points between segments were determined empirically by testing the full 
range of possible transition points and selecting the model with the best Bayesian Information 
Criterion26. The number of segments was determined similarly. Finally, we added age and 
antipsychotic medication as time-varying covariates to resulting models to determine whether 
observed changes were independent from variation in these covariates.  
 
Results 
Description of clinical course 
Table 2 shows outcomes and antipsychotic medication use of the five diagnostic groups 
across the two decades. The pattern is notable for worse outcomes in schizophrenia. Differences 
among the other groups were less pronounced, although bipolar disorder with psychosis and 
psychotic depression often had better outcomes than substance-induced and other/undetermined 
psychoses. Importantly, within-group variability was substantial and often dwarfed between-
group differences. The overall pattern of clinical course over 20 years indicated that 
schizophrenia typically followed a chronic course (74.1% continuously ill), whereas an episodic 
course was common in bipolar disorder with psychosis (79.5%) and psychotic depression 
(66.7%), and the other two groups fell between them. Psychotic depression, substance-induced 
psychosis, and other/undetermined groups were too small (N<50) for planned analyses; 
therefore, we combined groups based on similarity of course, resulting in three larger categories: 
schizophrenia (N=175), MoDWP (N=137), and other (N=61). 
Next, we tested the significance of changes within the three groups from month 6 to each 
follow-up (Figure 1). The GAF remained stable or improved from month 6 through 48 for each 
group, but thereafter declined by 13 points in schizophrenia and 9 points in the other groups. 
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With regard to specific symptom dimensions, apathy-asociality also remained stable or improved 
through month 48, but then worsened (ds = .35 - .73, comparing year 20 to month 6). 
Inexpressivity improved through year 10, but by year 20 it returned to initial levels. Reality 
distortion symptoms were at stable low levels throughout the follow-up in MoDWP and other 
psychoses. In schizophrenia, reality distortion was stable through month 48, but then increased 
substantially (d = .45), whereas disorganization worsened even more (d = .61). These increases 
are particularly notable given that rates of antipsychotic medication use remained largely stable 
in schizophrenia, while they declined dramatically in other disorders (eFigure 1). In contrast, 
depression decreased and mania/excitement remained stable across the interval.  
We also compared clinical course among disorders, focusing on the initial outcome 
(month 6), long-term outcome (year 20), and the change between these waves (eTable 1). 
Compared to MoDWP, schizophrenia had consistently worse outcomes on GAF, apathy-
asociality, inexpressivity, reality distortion, and disorganization. Moreover, worsening was 
greater in schizophrenia than in MoDWP on these outcomes, except for inexpressivity. No 
differences were observed between disorders on depression and mania/excitement. The only 
difference between other psychoses and MoDWP was higher reality distortion symptoms at year 
20 in the former. 
Although highly accurate, 10-year diagnosis may be confounded by illness course during 
the first decade. To consider the impact of this confounding, we repeated the analyses using 6-
month diagnosis (eFigure 2). Schizophrenia trajectories were virtually unchanged for GAF, 
apathy-asociality, inexpressivity, reality distortion, and disorganization, whereas MoDWP and 
other psychoses showed more severe trajectories with 6-month vs 10-year diagnosis. This pattern 
is consistent with misclassification, namely that some cases who followed schizophrenia 
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trajectory were assigned other diagnoses at month 6. Indeed, we previously found in this cohort 
that many 6-month non-schizophrenia cases were later reclassified as schizophrenia, whereas 
few people shifted out of schizophrenia17. The reanalysis with 6-month diagnosis had little 
impact on trajectories of mood symptoms. 
Trajectories of diagnostic groups 
 Next, we used multi-level spline regression to estimate trajectories of the three groups 
across the entire follow-up for each outcome. The number of segments was determined 
empirically (eTable 2). Selected models were either linear (i.e., had only one segment) or 
allowed one change in trajectory’s slope (i.e., had two segments). Estimated trajectories (Figure 
2) closely resembled longitudinal patterns obtained by smoothing raw data (eFigure 3), which 
suggests that models represented the data well. Change per year and its significance are given in 
Table 3 (unadjusted columns). 
GAF declined significantly in schizophrenia; it improved in MoDWP and other 
psychoses initially, but declined significantly after approximately year 7 (Figure 2). Apathy-
asociality worsened in all groups, although in MoDWP it improved through about year 7 and 
then deteriorated well beyond the initial level. Inexpressivity lessened until approximately year 7 
but increased thereafter, except for other psychoses where the trajectory was flat throughout. 
Reality distortion increased in schizophrenia but remained stable in the other groups. 
Disorganization worsened in all disorders. Depression improved in all groups, but in MoDWP 
improvement plateaued at year 2. Mania/excitement did not change significantly across the 
interval. Changes in GAF were primarily driven by changes in apathy-asociality and reality 
distortion (eTable 3). 
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To test whether observed patterns reflect effects of aging or changes in treatment rather 
than illness evolution, we repeated the analyses controlling for age and antipsychotic use at each 
assessment point (Table 3). Age had no effect on psychopathology after accounting for time 
since baseline. Antipsychotic use was associated with worse GAF, inexpressivity, and apathy-
asociality overall, but with less disorganization and mania/excitement in schizophrenia. Also, 
antipsychotic use was associated with lower reality distortion in schizophrenia, but greater 
symptoms in other psychoses. This pattern may indicate medication side effects or self-selection 
(e.g., sicker participants are more likely to receive antipsychotics long-term). Adjustment for 
these two variables did not change findings for illness trajectories except that three slopes 
became non-significant in other psychoses and two became non-significant in MoDWP. 
Adjustments for various other potential confounds had little impact on the pattern of results (see 
eResults and eTable 4). 
 
Discussion 
 We found that schizophrenia exhibits substantial and consistent decline over the two 
decades following first hospitalization. Mean GAF score of this group decreased from 49 (at 6-
month assessment) to 36 (20-year assessment), and the latter score indicates impairment in 
reality testing, communication, or pervasive disability. With regard to specific symptom 
dimensions, worsening was observed in apathy-asociality, reality distortion, and disorganization. 
MoDWP were less severe than schizophrenia (mean GAF of 65 at 6-month), but they also 
showed worsening on GAF, apathy-asociality, and disorganization. This decline was smaller 
(e.g., nine points on GAF) than that in schizophrenia. The decline began five to eight years after 
the first hospitalization. Depression and mania showed no signs of worsening in any disorders.  
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Overall, 74% participants with schizophrenia were continuously ill, compared to 14% of 
MoDWP, and most of the rest of these groups experienced multiple episodes during the 20-year 
interval. 
Our results align with the Kraepelinian view of schizophrenia as following a downward 
trajectory. The illness worsened gradually, but in the second decade the decline become 
noticeable. Treatment initiation improved reality distortion and disorganization substantially, as 
indicated by change from baseline to month 6, but symptoms gradually returned, undoing many 
treatment gains by year 20. Contrary to Kraepelin’s observations, MoDWP also experienced 
significant worsening, although less pronounced than schizophrenia and limited to negative 
symptoms (reality distortion and disorganization remained low). Of note, mood symptoms 
showed a different pattern, either improving or remaining consistently low. 
Importantly, heterogeneity within diagnostic groups was substantial, and a number of 
participants achieved good outcomes (GAF>60 at year 20): 42% of MoDWP, 31% of other 
psychoses, and 4% of schizophrenia. We previously reported that rank-order stability over 20 
years is modest for negative symptoms (test-retest r ~ .40) and low for reality distortion and 
disorganization (r ~ .20)11. Thus, trajectories of individual participants varied around the mean 
trend for their group with some increasing and others decrease. 
To minimize misclassification, a common problem early in the course of psychosis17, we 
used consensus diagnoses based on 10 years of observation. Such diagnoses are very accurate 
but are influenced by illness course. To examine this confounding, we repeated analyses using 6-
month diagnoses. This had little impact on trajectories of schizophrenia, other than moderating 
the increase of psychotic symptoms somewhat. In contrast, other disorders looked consistently 
worse when 6 month diagnoses were used. This pattern can be explained by initial 
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misclassification of schizophrenia cases as non-schizophrenia psychoses. Nevertheless, illness 
course is integral to diagnostic criteria (e.g., 6 months of symptoms are required for 
schizophrenia diagnosis) and some circularity is inherent in comparing course of diagnostic 
groups. 
Trajectories of reality distortion were notable in that symptoms worsened in 
schizophrenia, despite consistently high rates of antipsychotic medication use across the two 
decades (~80% at each wave). This pattern is consistent with suggestions that antipsychotics may 
lose some of their effectiveness in the long-term and may even lead to paradoxical effects27,28  
perhaps due to treatment non-adherence and relapses29. Also, changes in specific medication 
prescribed or its dose may contribute to this finding. Our study cannot directly test these 
possibilities as they require an experimental design. 
Present findings paint a bleaker picture than the DOSMeD study, where only 29% of 
participants with schizophrenia were continuously ill and more than half had GAF>60 after two 
decades7. A variety of factors distinguish the U.S. from other countries included in DOSMeD 
study (India, Russia, Japan, England, Ireland, and Czech Republic). Availability of family 
support and community integration may contribute to differences in outcomes8, but a particularly 
salient issue is access to treatment. The Suffolk County cohort received community services 
typical of the U.S. and experienced a substantial unmet need for care30, which may account for 
poor outcomes especially compared to countries with universal health care.  
On the other hand, our results are consistent with meta-analyses that found outcome in 
schizophrenia to be almost universally poor 31,32. Moreover, a systematic review of FEP studies 
found that during first decade of illness outcomes in treatment studies (mean GAF=66) were 
much better than in observational studies (mean GAF=50), and the latter are consistent with 
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initial outcomes in the present cohort. The current study extends these reviews by documenting 
timing and pace of decline across multiple symptom dimensions.  
Our findings are also consistent with evidence of accelerated neurodegeneration in 
schizophrenia33 that may underpin worsening negative symptoms. Poor physical health also may 
contribute to worse clinical course, as it limits daily functioning, impairs cognitive performance, 
and is common in psychotic disorders34. We observed significant effects of poor health in 
MoDWP but not in other groups (eTable 4). Furthermore, our results for MoDWP are consistent 
with studies that reported functional impairment and residual symptoms to be very common in 
psychotic bipolar disorder years after first admission35.   
 Current results should not be interpreted as an indication that good outcomes are out of 
reach. There is extensive evidence that aggressive treatment, especially psychotherapy and 
vocational rehabilitation, can substantially improve outcomes36-38. Moreover, 10-year follow-ups 
of FEP in Denmark and the United Kingdom, countries with universal access to psychiatric 
services, found relatively good outcomes with no evidence of decline and few continuously ill 
participants both in non-schizophrenia and schizophrenia groups5,6. It is possible that with better 
care, outcomes in the U.S. would mirror those of Denmark and the United Kingdom. 
 This study is the first in the U.S. to follow an epidemiologically-defined large FEP cohort 
long-term. Nevertheless, it has several limitations. First, it is limited to one geographic location 
and does not necessarily reflect illness course in other societies. Nevertheless, present findings 
call attention to a glaring public health problem in the U.S. Second, attrition was non-negligible; 
32% of survivors could not be contacted or refused participation. However, attrition analyses 
suggest that non-participants were largely similar to participants, except for slightly higher 
likelihood of being a minority and more severe psychotic symptoms at baseline, both risk factors 
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for worse outcome29,39. Thus, the present results may underestimate severity of clinical course. 
Third, assessments began at first admission rather than first onset. Fortunately, length of pre-
admission illness was short relative to the follow-up with median duration of untreated psychosis 
of 40 days (only 27% were ill for more than a year). Fourth, we did not measure mania 
symptoms dimensionally and had to rely on a proxy measure, BPRS Excitement. Fifth, the study 
focused on symptoms and global outcome, and did not consider dimensions of functioning. 
Functioning was beyond the scope of the present paper focused on symptom burden, but we are 
reporting several functional outcomes in another publication40.   
Conclusions 
Present results suggest an alarming public health problem, a high symptom burden in 
psychotic disorders that increases with time and ultimately may undo initial treatment gains. 
Previous studies suggest that better care may preempt this decline. In the U.S., psychotic 
disorders are associated with a large unmet need for care, and the current study highlights this 
shortcoming as an urgent priority. Reasons for the decline are unclear and numerous 
explanations exist. Greater research attention to mid and late course of psychotic disorders is 
needed to identify factors that drive this decline, just as it unfolds, and learn how to preempt it. 
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Table 1. Baseline Characteristics of Follow-up Cohort (N=373) and Surviving Non-Participants (N=176)  
 20-Year Cohort 
N (%) 
Non-Participants 
N (%) 
p-value 
Demographic characteristics    
  Male 222 59.5% 97 55.1% .329 
  Age less than 28                          195 52.3% 87 49.4% .533 
  Blue collar household 165 44.2% 75 42.6% .721 
  Race, Caucasian 290 77.7% 119 67.6% .011 
Research diagnosis (last available)      
Schizophrenia spectrum disorders 175 46.9% 73 41.5% .531 
Bipolar I disorder with psychosis  94 25.2% 41 23.3%  
Major depressive disorder with psychosis  43 11.5% 25 14.2%  
Substance-induced psychosis  25 6.7% 16 9.1%  
Other/undetermined psychosis 36 9.7% 21 11.9%  
Baseline Ratings Mean  (SD) Mean  (SD)  
GAF (best month in year before hospitalization) 58.17 14.25 59.98 14.87 .172 
Apathy-asociality 9.38 7.61 8.90 6.21 .435 
Inexpressivity 7.32 8.08 6.28 6.98 .142 
Reality distortion 10.73 8.71 12.78 10.39 .024 
Disorganization 6.89 6.52 6.32 5.89 .321 
Depression 17.52 5.38 17.22 4.93 .509 
Mania/Excitement  1.66 1.16 1.53 1.07 .192 
a Surviving nonparticipants were patients who completed baseline assessment but did not participate in the 
20-year follow-up assessment and were not known to be deceased: 78 refused, 70 were lost, 15 were 
impossible to interview (abroad or institutionalized), and 13 provided brief updates insufficient for 
target ratings. GAF = global assessment of functioning. 
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Table 2. Characteristics of diagnostic groups over time 
 
Outcome 
Schizophrenia 
 
Bipolar disorder 
with psychosis 
 
Psychotic 
depression 
 
Substance-
induced 
 
Other/ 
Undetermined 
 Mean SD   Mean SD   Mean SD   Mean SD   Mean SD 
GAF 
             
 baseline 52.65 14.17 
 67.83 9.44  60.30 12.99  57.68 11.92  57.53 14.64 
 6 months 49.34 13.18 
 66.37 11.90  61.45 13.94  61.74 11.45  62.73 12.67 
 24 months 50.39 12.90 
 69.14 10.83  64.98 12.31  64.65 11.45  60.96 14.39 
 48 months 49.27 12.21 
 70.05 11.81  67.93 12.03  65.05 13.06  63.13 15.10 
 10 years 44.06 10.67 
 66.95 13.14  65.61 11.72  61.39 13.99  60.93 15.49 
 20 years 35.79 10.57 
 57.79 16.78  52.81 16.06  53.88 16.82  51.33 19.03 
Apathy-asociality              
 baseline 12.11 7.36 
 4.95 5.74  10.67 7.60  8.40 5.61  6.86 8.26 
 6 months 11.55 7.92 
 5.23 6.05  8.51 7.87  7.35 4.98  5.69 7.11 
 24 months 11.31 6.64 
 3.76 5.20  6.97 7.32  5.87 5.74  6.36 6.90 
 48 months 11.30 6.70 
 3.70 4.67  5.67 6.88  4.47 4.90  7.67 7.12 
 10 years 13.99 8.14 
 3.53 4.75  4.60 5.77  7.87 7.96  6.62 8.13 
 20 years 17.56 8.84 
 8.00 7.70  10.11 8.52  9.74 9.05  11.51 10.23 
Inexpressivity              
 baseline 10.22 8.39 
 3.86 6.10  6.60 8.43  4.28 5.70  5.28 7.23 
 6 months 10.52 8.92 
 2.64 4.79  5.00 7.09  3.30 4.20  3.92 6.58 
 24 months 9.48 8.19 
 1.80 2.63  3.68 5.62  3.22 5.14  2.68 4.64 
 48 months 8.82 8.82 
 1.61 3.15  2.24 3.66  1.53 3.22  3.72 5.30 
 10 years 7.99 7.67 
 1.68 3.98  1.87 4.15  2.40 4.57  2.83 6.49 
 20 years 10.32 10.37 
 3.69 5.45  4.26 7.13  4.00 6.17  7.90 11.34 
Reality distortion              
 baseline 12.54 9.36 
 10.77 8.87  6.23 6.00  8.40 6.89  8.83 6.05 
 6 months 4.26 7.44 
 0.56 1.29  2.81 4.56  1.52 3.19  2.50 4.67 
 24 months 4.41 6.36 
 0.99 3.19  0.92 2.74  1.83 3.66  3.40 6.30 
 48 months 4.03 6.67 
 1.05 2.78  0.94 2.52  1.53 3.01  3.44 7.96 
 10 years 6.66 8.24 
 0.46 1.86  1.03 2.29  1.78 3.25  3.07 5.69 
 20 years 7.31 9.34 
 0.84 2.16  0.93 2.32  2.73 4.79  3.47 5.92 
Disorganization              
 baseline 7.19 7.00 
 8.97 6.05  1.86 2.96  5.68 5.37  6.89 6.07 
 6 months 2.99 5.14 
 1.61 3.00  0.89 1.37  0.70 1.15  2.08 2.64 
 24 months 2.99 4.35 
 2.19 3.93  1.08 2.13  2.09 3.63  3.36 5.22 
 48 months 3.65 4.87 
 2.34 4.22  0.73 1.86  0.47 1.02  2.33 3.07 
 10 years 4.27 6.00 
 1.79 3.74  0.94 2.45  1.29 2.24  3.64 6.20 
 20 years 6.16 7.28 
 3.21 5.22  2.45 4.33  2.07 3.76  5.71 6.32 
Depression              
 baseline 17.04 5.02 
 16.85 5.13  22.21 5.23  16.96 5.83  16.42 5.10 
 6 months 13.55 4.03 
 12.13 3.35  15.51 5.51  12.70 3.97  13.04 5.08 
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 24 months 13.20 4.46 
 11.16 3.47  12.86 5.27  12.52 4.67  13.72 5.00 
 48 months 10.69 3.79 
 9.94 3.07  12.00 5.72  10.53 3.42  11.72 5.38 
 10 years 11.92 3.76 
 10.99 3.47  13.35 5.10  12.55 4.27  11.37 3.25 
 20 years 11.60 3.28 
 11.87 3.93  13.35 4.57  11.43 3.51  12.45 3.85 
Mania/Excitement              
 baseline 1.49 1.00 
 2.13 1.39  1.07 0.34  1.96 1.34  1.78 1.22 
 6 months 1.21 0.66 
 1.44 0.90  1.00 0.00  1.26 0.75  1.20 0.71 
 24 months 1.22 0.65 
 1.41 0.92  1.14 0.48  1.22 0.60  1.48 1.08 
 48 months 1.33 0.68 
 1.47 0.96  1.12 0.42  1.21 0.54  1.39 0.78 
 10 years 1.29 0.80 
 1.35 0.90  1.15 0.48  1.57 1.20  1.59 1.37 
 20 years 1.28 0.83 
 1.34 0.87  1.13 0.47  1.14 0.48  1.21 0.63 
                
  N % 
 N %  N %  N %  N % 
Use antipsychotics              
 baseline 152 86.9% 
 82 87.2%  31 72.1%  15 60.0%  31 86.1% 
 6 months 148 84.6% 
 63 67.0%  24 55.8%  9 36.0%  20 55.6% 
 24 months 136 79.5%  37 39.4%  18 41.9%  4 16.7%  14 40.0% 
 48 months 122 70.1% 
 32 34.0%  10 23.3%  4 16.0%  12 33.3% 
 10 years 142 87.1% 
 34 40.0%  8 20.0%  6 26.1%  7 25.9% 
 20 years 117 81.8% 
 30 36.1%  10 25.0%  4 20.0%  10 37.0% 
Illness pattern over 20 years              
 Single episode 1 0.6%  10 11.4%  8 19.0%  4 17.4%  10 38.5% 
 Multiple Episodes 43 25.3%  70 79.5%  28 66.7%  13 56.5%  8 30.8% 
 Continuous illness 126 74.1%  8 9.1%  6 14.3%  6 26.1%  8 30.8% 
 
Note: For apathy-asociality, inexpressivity, reality distortion, and disorganization scales, zero indicates no 
symptoms; depression scale ranges from 9 (no symptoms) to 27; mania/excitement range from one 
(none) to seven (very severe). Sample size for symptom outcomes is N = 153, 148, 145, 166, and 
175 for schizophrenia (6-month to 20-year wave, respectively); 83, 81, 82, 86, and 94 for bipolar 
disorder with psychosis; 38, 41, 40, 41, and 43 for psychotic depression; 26, 28, 23, 29, and 36 for 
substance-induced psychosis; and 23, 23, 21, 23, and 25 for other/undetermined psychoses. 
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Table 3. Changes in symptoms over time: unadjusted and adjusting for age and antipsychotic medications 
 
 Schizophrenia   MoDWP  Other Psychoses 
 Unadjusted  Adjusted  Unadjusted  Adjusted  Unadjusted  Adjusted 
  B p-value 
 
B p-value  B p-value B p-value  B p-value B p-value 
GAF                      
   Time(S1) -0.70 <.001*  -0.59 <.001*  1.52 <.001*  1.26 <.001*   0.49 .119  0.60 .097 
   Time(S2) --- ---  --- ---  -0.98 <.001*  -0.94 <.001*  -0.99 <.001*  -0.60 .011 
   Age --- ---  -0.10 .231  --- ---  -0.07 .415  --- ---  -0.31 .055 
   Antipsychotics --- ---  -0.84 .480  --- ---  -4.78 <.001*  --- ---  -5.19 .004* 
Apathy-asociality                 
   Time(S1) 0.34 <.001*  0.26 <.001*  -0.59 <.001*  -0.58 <.001*  0.22 <.001*  0.05 .571 
   Time(S2) --- ---     0.48 <.001*  0.40 <.001*  --- ---  --- --- 
   Age --- ---  0.09 .133  --- ---  0.09 .014  --- ---  0.16 .045 
   Antipsychotics --- ---  2.59 .001*  --- ---  2.33 <.001*  --- ---  1.90 .058 
Inexpressivity                  
   Time(S1) -0.51 <.001* 
 
-0.55 <.001*  -0.45 <.001* 
 
-0.29 .019  0.12 .035 
 
0.11 .245 
   Time(S2) 0.27 <.001* 
 
0.32 .002*  0.23 <.001* 
 
0.21 <.001*  --- ---  --- --- 
   Age --- ---  0.00   .957  --- ---  -0.02 .453  --- ---  0.01 .912 
   Antipsychotics --- ---  
2.59 .003* 
 --- ---  
2.04 <.001* 
 --- ---  
1.98 .035* 
Reality distortion   
   
   
  
     
   Time 0.18 <.001* 
 
0.20 .003*  -0.02 .102 
 
-0.04 .056  0.03 .299 
 
-0.04 .553 
   Age --- ---  -0.02 .679  --- ---  0.02 .124  --- ---  0.07 .208 
   Antipsychotics --- ---  -1.82 .027  --- ---  0.54 .020  --- ---  2.24 .001* 
Disorganization   
   
   
  
     
   Time 0.18 <.001* 
 
0.18 .001*  0.07 <.001* 
 
0.05 .064  0.11 .001* 
 
0.03 .602 
   Age --- ---  -0.01 .875  --- ---  0.02 .393  --- ---  0.07 .146 
   Antipsychotics --- ---  -1.65 .005*  --- ---  0.00 .990  --- ---  -0.05 .939 
Depression     
   
   
  
     
   Time(S1) -0.10 <.001* 
 
-0.08 .016  -0.99 .001* 
 
-0.89 .002*  -0.06 .065 
 
-0.15 .007* 
   Time(S2) --- ---  --- ---  0.03 .166 
 
0.00 .969  --- ---  --- --- 
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   Age --- ---  -0.02 .466  --- ---  0.04 .130  --- ---  0.08 .056 
   Antipsychotics --- ---  0.72 .088  --- ---  0.83 .033  --- ---  1.49 .019 
Mania/Excitement   
   
   
  
     
   Time 0.00 .313 
 
0.01 .149  0.00 .696 
 
0.00 .887  0.00 .889 
 
-0.01 .368 
   Age --- ---  -0.01 .291  --- ---  0.00 .549  --- ---  0.01 .332 
   Antipsychotics --- ---  -0.20 .009*  --- ---  0.09 .229  --- ---  0.02 .896 
 
Note: B = change in symptom score per year; dashes indicate non-applicable (i.e., effects not included in the model). MoDWP = mood disorder 
with psychosis. S1 is first segment of the 20-year interval or the entire interval, if we model has only one segment; S2 is the second segment. 
Transition point between segments for GAF was at year 5 in MoDWP and year 7 in other psychoses; for apathy-asociality it was at year 7 in 
MoDWP; for inexpressivity it was at year 6 in MoDWP and year 7 in schizophrenia; for depression it was at year 2 in MoDWP. 
Sample size is N = 175 for schizophrenia, 137 for MoDWP, and 61 for other psychoses. 
*p <.01 
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Figure 1. Outcomes in major diagnostic groups: means at each follow-up and comparison to month 6 
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Note: Blue = schizophrenia, orange = mood disorders with psychosis, grey = other psychoses. 
Sample size is N = 153, 148, 145, 166, and 175 for schizophrenia (6-month to 20-year wave, respectively), 121, 122, 122, 127, and 137 for 
MoDWP, and 49, 51, 44, 52, and 61 for other psychoses. 
*p<.01 for difference between 6-month and a later follow-up 
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Figure 2. Trajectories of diagnostic groups post-admission modeled using spline regression  
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Note: Blue line is schizophrenia, orange line is mood disorders with psychosis, grey line is other psychoses 
Sample size is N = 175 for schizophrenia, 137 for MoDWP, and 61 for other psychoses. 
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eMethods 
DOSMeD rating of overall pattern of clinical course considers both psychotic and mood symptoms. The rating 
consists of eight mutually exclusive categories22: 
1. single psychotic episode followed by full symptom remission 
2. single psychotic episode followed by incomplete remission 
3. single psychotic episode followed by one or more non-psychotic episodes, with full symptom remissions 
between all or most of the episodes. 
4. single psychotic episode followed by one or more non-psychotic episodes, with incomplete remissions 
between all or most of the episodes. 
5. two or more psychotic episodes, with full symptom remissions between all or most of the episodes. 
6. two or more psychotic episodes, with incomplete remissions between all or most of the episodes. 
7. continuous psychotic illness (no remission): 
8. continuous non-psychotic illness (no remission); psychotic symptoms may have been present for some time 
but non-psychotic symptoms predominate throughout. 
Due to small number of cases in some of the categories, we aggregated eight categories into three common 
patterns: single episode (categories 1 and 2), multiple episodes (categories 3, 4, 5 and 6), and continuous illness 
(categories 7 and 8). 
The BPRS Excitement rating reflects affective core of mania, but does not capture associated symptoms. 
Interviewers are instructed to rate “heightened emotional tone, including irritability and expansiveness 
(hypomanic affect).” Rating scale ranges from 0 (not observed) to 7 (very severe). 
As reported previously, reliability of ratings from baseline to year 10 was excellent with intraclass 
correlations ≥ .7511,16,17. At year 20, interviewers rated 30 randomly selected audio recordings of 10-year 
interviews to evaluate consistency between waves. Intraclass correlations were .94 for Apathy-Asociality, .97 
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for Reality Distortion, and .93 for Disorganization, .96 for BPRS Excitement, and .87 for SCID Depression. 
Inexpressivity could not be rated from audio recordings. 
 
Multi-level spline regression was used to estimate outcome trajectories of the diagnostic groups from 
month 6 to year 20. This model describes individual trajectory of each participant in terms of starting level 
(intercept) and subsequent progression (captured by slope in each segment). Intercept was modeled as a random 
effect (parameter that varies between people). Since change may be non-linear, we compared two-segment 
spline models (i.e., trajectory is continuous but has one slope in the first segment and a different slope in the 
second segment) to single-segment models (consistent change throughout the entire follow-up). In the two-
segment model, transition between segments was determined empirically by selecting time point for transition 
that maximized model fit. Model selection was done in each diagnostic group independently. After a spline 
model was selected, we estimated mean trajectory for the group and calculated significance of slopes to test for 
change in the outcome over time. Next, we added time-varying covariates to the model (e.g., age, medication) 
to determine whether changes in these variables explain changes in an outcome over time. Analyses were 
performed in in SAS version 9.2 with PROC GLIMMIX. 
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eResults 
Although focus of the study is on trajectories of symptoms, we thought it informative to also describe patterns of 
medication use over time (eFigure 1). Antipsychotics were used at a consistently high rate (~80%) in schizophrenia group, 
other than a small reduction at year 10; while use of antipsychotics declined substantially in MoDWP (from 63% at month 
6 to 32% at year 20), and other psychoses showed a similar decline but it did not reach statistical significance. In contrast, 
use of antidepressants and mood stabilizers remained unchanged in all groups from month 6 to year 20, except for a small 
increase in mood stabilizer use in schizophrenia (from 15% to 25%).    
We examined six additional time-varying covariate that might explain slopes of trajectories: (1) hospitalizations 
(annual rate in the interval preceding the assessment), (2) number of medical conditions the participant reported being 
treated for or diagnosed with during the interval (assessed with the chronic conditions module of the Composite 
International Diagnostic Interview41, which includes diabetes, hypertension, other heart problems, gastrointestinal 
problems, asthma, arthritis, cancer, liver problems, thyroid problems, headaches, seizures, eye problems, hearing 
problems, and HIV), (3) major depressive episode in the interval (assessed with the SCID21), (4) manic episode in the 
interval (assessed with the SCID21), (5) number of medication visits to a mental health provider (monthly rate averaged 
across six months prior to the assessment), and (6) number of psychotherapy visits (monthly rate averaged across six 
months prior to the assessment). Data were obtained by interviews with participants, interviews with significant others, 
and review of medical records when available. 
 These variables were added to spline regression models that controlled for age and antipsychotic use, resulting in 
eight time-varying covariates altogether. Simultaneous adjustment for these covariates generally did not alter the course of 
the seven outcomes in the three diagnostic groups, except that increase in apathy-asociality became non-significant in 
other psychoses after controlling for psychotherapy visits, initial decrease in inexpressivity became non-significant in 
MoDWP after controlling for antipsychotics, increase in disorganization was fully explained in MoDWP by occurrence of 
manic episodes and hospitalizations in the interval, and decrease in depression became non-significant in schizophrenia 
and MoDWP after controlling for occurrence of major depressive episodes in the interval (eTable 4). Thus, even 
controlling for a range of covariates, we observed a global decline (indicated by the GAF) in all groups and an increase in 
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psychosis specific to schizophrenia. This suggests that the downward clinical course observed in this cohort is not due to 
aging, mood episodes, physical comorbidities, or changes in treatment, although our ability to test treatment effects is 
limited by the observational nature of the study. 
 
41Kessler, R. C., & Üstün, T. B. (2004). The world mental health (WMH) survey initiative version of the world health 
organization (WHO) composite international diagnostic interview (CIDI). International journal of methods in psychiatric 
research, 13(2), 93-121.  
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eTable 1. Differences between disorders at month 6, year 20, and in change from month 6 to year 20 
 
  MoDWP  Other Psychoses     Schizophrenia   
    N M SD  N M SD p-value   N M SD p-value 
GAF              
 6mo 121 64.83 12.73 
 49 62.27 12.00 .229  153 49.34 13.18 .000 
 20yr 137 56.23 16.66 
 61 52.37 18.05 .144  175 35.79 10.57 .000 
 20yr-6mo 121 -8.86 15.72 
 49 -8.64 17.16 .933  153 -13.19 14.08 .017 
Inexpressivity          
    
 6mo 117 3.38 5.70 
 49 3.63 5.55 .797  146 10.52 8.92 .000 
 20yr 93 3.88 6.03 
 39 6.00 9.29 .195  129 10.32 10.37 .000 
 20yr-6mo 84 0.33 7.15 
 31 3.39 10.10 .073  111 0.44 10.84 .933 
Apathy-asociality         
    
 6mo 117 6.26 6.82 
 49 6.47 6.20 .857  146 11.55 7.92 .000 
 20yr 128 8.67 8.00 
 51 10.75 9.68 .178  149 17.56 8.84 .000 
 20yr-6mo 110 2.58 7.97 
 41 4.19 8.58 .280  126 6.13 8.86 .001 
Reality distortion         
    
 6mo 117 1.27 2.95 
 49 2.04 4.03 .233  146 4.26 7.44 .000 
 20yr 128 0.87 2.20 
 52 3.15 5.44 .005  151 7.31 9.34 .000 
 20yr-6mo 110 -0.40 3.42 
 42 1.00 4.80 .089  126 3.77 11.47 .000 
Disorganization          
    
 6mo 117 1.38 2.61 
 49 1.43 2.17 .917  146 2.99 5.14 .001 
 20yr 126 2.97 4.96 
 51 4.14 5.62 .173  148 6.16 7.28 .000 
 20yr-6mo 110 1.76 5.51 
 41 1.87 4.61 .910  124 3.79 7.20 .016 
Depression          
    
 6mo 117 13.20 4.42 
 49 12.88 4.55 .675  146 13.55 4.03 .502 
 20yr 124 12.35 4.18 
 49 12.01 3.70 .625  141 11.60 3.28 .111 
 20yr-6mo 106 -0.96 5.30 
 40 -0.97 4.21 .991  118 -1.90 4.54 .154 
Excitement          
    
 6mo 117 1.30 0.77 
 48 1.23 0.72 .590  146 1.21 0.66 .290 
 20yr 122 1.27 0.77 
 49 1.18 0.57 .476  147 1.28 0.83 .932 
 20yr-6mo 105 0.00 1.03 
 39 -0.05 0.89 .783  126 0.13 0.87 .281 
 
Note: p-values reflect t-tests comparing schizophrenia and other psychoses to mood disorders with psychosis (MoDWP). 
Bold indicates statistically significant differences (p < .05).  
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eTable 2. Fit of spline models 
          
  segments Schizophrenia   MoDWP   Other 
Symptom   BIC ΔBIC   BIC ΔBIC   BIC ΔBIC 
GAF          
 1 5603 -- 4533 -- 1912 -- 
 2 5596 7 
 
4483 50 
 
1901 11 
 3 5589 7 
 
4479 3 
 
1896 4 
Apathy-asociality        
 1 4772 --  3745 --  1537 -- 
 2 4767 6  3710 35  1534 3 
 3 4760 6  3706 3  1533 1 
Inexpressivity         
 1 4600 -- 3057 -- 1377 -- 
 2 4586 14 
 
3040 16 
 
1373 5 
 3 4579 7 
 
3039 2 
 
1369 4 
Reality distortion        
 1 4870 -- 2701 -- 1373 -- 
 2 4869 1 
 
2701 0 
 
1372 1 
 3 4866 2 
 
2702 -2  1372 0 
Disorganization         
 1 4226 -- 3023 -- 1300 -- 
 2 4226 0  3022 1 
 
1301 0 
 3 4224 1  3020 2  1300 1 
Depression         
 1 3749 -- 3205 -- 1309 -- 
 2 3744 4 
 
3191 14 
 
1308 1 
 3 3743 1 
 
3191 -1  1307 1 
Mania/Excitement         
 1 1502 -- 1326 -- 589 -- 
 2 1504 -2 
 
1329 -3  585 4 
  3 1507 -3   1332 -3   584 2 
  
Note: BIC = Bayesian Information Criterion. Bold indicates selected model (less parsimonious model was selected if it 
improved BIC by at least 10 points). Analyses were stratified by primary diagnosis. MoDWP = mood disorders with 
psychosis. Sample size is N = 175 for schizophrenia, 137 for MoDWP, and 61 for other psychoses. 
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eTable 3. Changes in symptoms explain contemporaneous changes in GAF  
 
 Schizophrenia       MoDWP  Other Psychoses 
  β p-value   β p-value   β p-value 
Inexpressivity -0.11 .0005  -0.11 .0005  0.00 .9965 
Apathy-asociality -0.45 <.0001  -0.49 <.0001  -0.53 <.0001 
Reality distortion -0.25 <.0001  -0.05 .0414  -0.29 <.0001 
Disorganization -0.18 <.0001  -0.08 .0195  -0.07 .1521 
Depression 0.07 .0167  -0.02 .5919  -0.02 .6760 
Excitement 0.09 .0081  -0.06 .0441  -0.03 .5355 
 
To evaluate contributions of individual symptoms to global outcome, we constructed a multi-level model (with random 
intercept and slopes) for GAF regressed on the six symptom dimensions treated as time-varying predictors. The predictors 
entered the model simultaneously. All predictors were converted to z-scores prior to analysis to ensure comparability of 
effect sizes. Sample size is N = 175 for schizophrenia, 137 for MoDWP, and 61 for other psychoses. 
p < .05 effects are bolded. 
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eTable 4. Changes in symptoms over time: unadjusted and adjusting for eight time-varying covariates 
  Schizophrenia   MoDWP   Other Psychoses 
 Unadjusted   Adjusted 
 Unadjusted  Adjusted  Unadjusted  Adjusted 
  B p-value 
 
B p-value  B p-value B p-value  B p-value B p-value 
GAF                  
   Time(S1) -0.7 <.001*  -0.56 <.001*  1.52 <.001*  0.89   .006*  0.49 .119  0.59 .145 
   Time(S2) --- ---  --- ---  -0.98 <.001*  -0.93 <.001*  -0.99 <.001*  -0.70   .007* 
   Age --- ---  -0.11 .215  --- ---  0.01  .938  --- ---  -0.27 .113 
   Antipsychotics --- ---  -0.93 .485  --- ---  -4.00 <.001*  --- ---  -4.99 .016 
   Hospitalizations --- ---  -0.64 .346  --- ---  -1.41   .006*  --- ---  -0.34 .764 
   Physical conditions --- ---  -0.48 .275  --- ---  -1.82 <.001*  --- ---  0.04 .954 
   MDE --- ---  0.03 .978  --- ---  -0.63 .500  --- ---  0.91 .627 
   Manic episode --- ---  4.40 .013  --- ---  1.16 .334  --- ---  3.32 .372 
   Medication visits --- ---  0.45 .456  --- ---  -0.55 .438  --- ---  -0.89 .515 
   Psychotherapy visits --- ---  0.16 .516  --- ---  0.02 .952  --- ---  -0.01 .987 
Apathy-asociality                  
   Time(S1) 0.34 <.001*  0.24   .001*  -0.59 <.001*  -0.43   .002*  0.22 <.001*  0.09 .342 
   Time(S2) --- ---  --- ---  0.48 <.001*  0.40 <.001*  --- ---  --- --- 
   Age --- ---  0.10 .105  --- ---  0.06 .109  --- ---  0.12 .116 
   Antipsychotics --- ---  2.43   .003*  --- ---  2.16 <.001*  --- ---  1.06 .323 
   Hospitalizations --- ---  0.22 .584  --- ---  0.65  .041  --- ---  0.62 .318 
   Physical conditions --- ---  0.28 .322  --- ---  0.98 <.001*  --- ---  0.60 .142 
   MDE --- ---  -0.58 .430  --- ---  0.25 .664  --- ---  1.25 .218 
   Manic episode --- ---  0.73 .500  --- ---  -0.66 .348  --- ---  -1.77 .382 
   Medication visits --- ---  0.40 .278  --- ---  0.21 .611  --- ---  0.22 .777 
   Psychotherapy visits --- ---  -0.13 .394  --- ---  0.11 .525  --- ---  0.64   .006* 
Inexpressivity    
              
   Time(S1) -0.51 <.001* -0.56 <.001*  -0.45 <.001*  -0.24 .072  0.12 .035  0.15 .095 
   Time(S2) 0.27 <.001* 
 
0.35   .002*  0.23 <.001*  0.24 <.001*  --- ---  --- --- 
   Age --- ---  0.02 .767 
 --- ---  -0.03 .345  --- ---  -0.01 .847 
   Antipsychotics --- ---  2.80   .003* 
 --- ---  2.04 <.001*  --- ---  1.54 .153 
   Hospitalizations --- ---  0.56 .238  --- ---  0.48 .056  --- ---  1.39 .031 
   Physical conditions --- ---  -0.25 .434  --- ---  0.13 .473  --- ---  0.46 .264 
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   MDE --- ---  -1.25 .147  --- ---  0.17 .710  --- ---  -0.61 .575 
   Manic episode --- ---  -2.04 .111  --- ---  -0.74 .196  --- ---  -0.91 .666 
   Medication visits --- ---  0.27 .509  --- ---  -0.06 .858  --- ---  0.48 .544 
   Psychotherapy visits --- ---  -0.05 .774  --- ---  -0.07 .606  --- ---  0.11 .646 
Psychosis   
 
              
   Time 0.18 <.001* 
 
0.20   .005*  -0.02 .102  -0.05 .019  0.03 .299  -0.02 .759 
   Age --- ---  -0.03 .609 
 --- ---  0.01 .381  --- ---  0.05 .363 
   Antipsychotics --- ---  -1.42 .116 
 --- ---  0.26 .315  --- ---  2.01   .006* 
   Hospitalizations --- ---  0.44 .341  --- ---  0.28 .046  --- ---  0.86 .039 
   Physical conditions --- ---  0.46 .125  --- ---  0.36 <.001*  --- ---  0.35 .185 
   MDE --- ---  -0.17 .837  --- ---  0.62 .012  --- ---  -0.40 .550 
   Manic episode --- ---  1.84 .129  --- ---  0.48 .111  --- ---  2.94 .030 
   Medication visits --- ---  -1.14   .006*  --- ---  -0.14 .451  --- ---  -0.51 .303 
   Psychotherapy visits --- ---  0.03 .866  --- ---  0.01 .941  --- ---  -0.17 .278 
Disorganization  
 
              
   Time 0.18 <.001* 
 
0.16   .004*  0.07 <.001*  0.00 .978  0.11 .001*  0.05 .290 
   Age --- ---  -0.01 .814 
 --- ---  0.03 .151  --- ---  0.03 .488 
   Antipsychotics --- ---  -1.23 .021 
 --- ---  -0.51 .167  --- ---  -0.02 .972 
   Hospitalizations --- ---  0.16 .541  --- ---  0.60   .001*  --- ---  0.81 .027 
   Physical conditions --- ---  0.18 .363  --- ---  0.10 .468  --- ---  0.14 .539 
   MDE --- ---  -0.57 .222  --- ---  -0.14 .689  --- ---  -0.02 .969 
   Manic episode --- ---  1.00 .150  --- ---  1.65 <.001*  --- ---  4.13 <.001* 
   Medication visits --- ---  -0.50 .036  --- ---  -0.34 .185  --- ---  -0.87 .049 
   Psychotherapy visits --- ---  -0.01 .946  --- ---  0.11 .311  --- ---  0.11 .428 
Depression   
 
              
   Time(S1) -0.1 <.001* 
 
-0.07 .027  -0.99 .001*  -0.45 .145  -0.06 .065  -0.12 .030 
   Time(S2) --- ---  --- --- 
 0.03 .166  -0.05 .177  --- ---  --- --- 
   Age --- ---  -0.01 .655 
 --- ---  0.02 .277  --- ---  0.03 .408 
   Antipsychotics --- ---  0.87 .044 
 --- ---  0.19 .629  --- ---  1.20 .070 
   Hospitalizations --- ---  0.14 .552  --- ---  0.11 .614  --- ---  -0.16 .696 
   Physical conditions --- ---  0.19 .175  --- ---  0.65 <.001*  --- ---  0.74   .003* 
   MDE --- ---  3.11 <.001*  --- ---  2.25 <.001*  --- ---  4.08 <.001* 
   Manic episode --- ---  1.47 .013  --- ---  1.21 .010  --- ---  -0.47 .726 
   Medication visits --- ---  -0.29 .147  --- ---  0.23 .424  --- ---  -0.22 .657 
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   Psychotherapy visits --- ---  0.12 .137  --- ---  0.21 .071  --- ---  -0.06 .701 
Mania/Excitement  
 
              
   Time 0.00 .313 
 
0.00 .427  0.00 .696  -0.01 .111  0.00 .889  -0.01 .561 
   Age --- ---  -0.01 .277 
 --- ---  0.00 .822  --- ---  0.00 .703 
   Antipsychotics --- ---  -0.15 .054 
 --- ---  0.02 .755  --- ---  -0.04 .785 
   Hospitalizations --- ---  0.02 .592  --- ---  0.06 .144  --- ---  0.01 .918 
   Physical conditions --- ---  0.02 .529  --- ---  0.02 .413  --- ---  -0.02 .725 
   MDE --- ---  -0.09 .221  --- ---  -0.09 .227  --- ---  0.02 .869 
   Manic episode --- ---  0.12 .247  --- ---  0.35 <.001*  --- ---  0.59 .026 
   Medication visits --- ---  -0.08 .023  --- ---  -0.01 .855  --- ---  -0.16 .103 
   Psychotherapy visits --- ---   0.00 .826   --- ---   -0.01 .688   --- ---   0.00 .932 
 
Note: B = change in symptom score per year. Dashes indicate non-applicable (i.e., effects not included in the model). MoDWP = mood disorder 
with psychosis. S1 is first segment of the 20-year interval or the entire interval, if we model has only one segment; S2 is the second segment. 
Transition point between segments for GAF was at year 5 in MoDWP and year 7 in other psychoses; for apathy-asociality it was at year 7 in 
MoDWP; for inexpressivity it was at year 6 in MoDWP and year 7 in schizophrenia; for depression it was at year 2 in MoDWP. Unadjusted 
results are the same as in Table 3 and are included for reference to help interpret impact of covariates on trajectories. Sample size is N = 175 for 
schizophrenia, 137 for MoDWP, and 61 for other psychoses. 
*p <.01 
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eFigure 1. Antipsychotics, antidepressants, and mood stabilizers in major diagnostic groups: prevalence at each 
follow-up and comparison to month 6 
 
 
 
Note: Blue = schizophrenia, orange = mood disorders with psychosis, grey = other psychoses. Sample size is N = 175, 
171, 174, 163, and 143 for schizophrenia (6-month to 20-year wave, respectively), 137, 137, 137, 125, and 123 for 
MoDWP, and 61, 59, 61, 50, and 47 for other psychoses. 
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*p<.01 for difference between 6-month and a later follow-up 
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eFigure 2.  Mean outcomes in major groups for 6-month and 10-year diagnoses 
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Note: To evaluate confounding of 10-year diagnosis with illness course, we compared trajectories for the three disorder groups defined according 
to 10-year diagnosis (solid lines) to groups defined by 6-month diagnosis (dashed lines). Blue = schizophrenia, orange = mood disorders with 
psychosis, grey = other psychoses. Sample size is N = 115, 110, 111, 124, and 129 for 6-month schizophrenia (6-month to 20-year wave, 
respectively), 147, 149, 146, 152, and 165 for 6-month MoDWP, and 61, 62, 54, 69, and 79 for 6-month other psychoses. Sample size is N = 153, 
148, 145, 166, and 175 for 10-year schizophrenia (6-month to 20-year wave respectively), 121, 122, 122, 127, and 137 for 10-year MoDWP, and 
49, 51, 44, 52, and 61 for 10-year other psychoses. 
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eFigure 3. Comparison of trajectories from spline regression to smoothing of raw data 
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Note: To evaluate accuracy of the multi-level spline regression models, we compared these models to smoothing data with 
locally weighted scatterplot smoothing (LOESS). LOESS uses weighted least squares to fit linear functions within a fixed 
neighborhood of each data point. It was applied for each diagnostic group separately. Solid lines are modeled curves from 
Figure 2. Dashed lines are LOESS curves. Blue = schizophrenia, orange = mood disorders with psychosis, grey = other 
psychoses. Sample size is N = 175 for schizophrenia, 137 for MoDWP, and 61 for other psychoses. 
